Amgen Inc. (formerly Applied Molecular Genetics Inc.) is a multinational biopharmaceutical company. The Company's largest selling product lines are Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.
Company Growth (employees)
Type
Public
HQ
Thousand Oaks, US
Founded
1980
Size (employees)
19,200 (est)
Website
amgen.com
Amgen was founded in 1980 and is headquartered in Thousand Oaks, US

Key People/Management at Amgen

Robert Bradway

Robert Bradway

Chairman and Chief Executive Officer
Suzanne Blaug

Suzanne Blaug

SVP, Global Marketing and Commercial Development

Amgen Office Locations

Amgen has offices in Thousand Oaks, San Francisco, South San Francisco, Bucharest and in 58 other locations
Thousand Oaks, US (HQ)
One Amgen Center Drive
Show all (62)

Amgen Financials and Metrics

Amgen Financials

Amgen's revenue was reported to be $23 b in FY, 2016
USD

Revenue (Q3, 2017)

5.8 b

Gross profit (Q3, 2017)

4.8 b

Gross profit margin (Q3, 2017), %

83%

Net income (Q3, 2017)

2 b

EBIT (Q3, 2017)

2.4 b

Market capitalization (13-Dec-2017)

130 b

Cash (30-Sep-2017)

3 b

EV

162.8 b
Amgen's current market capitalization is $130 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

18.7 b20.1 b21.7 b23 b

Revenue growth, %

7%8%6%

Cost of goods sold

3.3 b4.4 b4.2 b4.2 b

Gross profit

15.3 b15.6 b17.4 b18.8 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

4.7 b4.5 b5.2 b5 b5 b5.4 b5.7 b5.5 b5.7 b5.8 b5.5 b5.8 b5.8 b

Cost of goods sold

788 m1.1 b1.1 b1.1 b1 b1.1 b1 b1 b1.1 b1 b996 m1 b990 m

Gross profit

4 b3.4 b4.1 b4 b4 b4.3 b4.7 b4.5 b4.6 b4.8 b4.5 b4.8 b4.8 b

Gross profit Margin, %

83%76%79%79%79%80%82%82%82%82%82%82%83%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.8 b3.7 b4.1 b3.2 b

Accounts Receivable

2.7 b2.5 b3 b3.2 b

Inventories

3 b2.6 b2.4 b2.7 b

Current Assets

27.4 b34.7 b38.5 b46 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

8.3 b3.7 b4.4 b3.7 b2.9 b3.8 b3.2 b2.9 b2.6 b3.5 b3.4 b2.6 b3 b

Accounts Receivable

2.7 b2.5 b2.7 b2.4 b2.5 b2.8 b2.9 b3.1 b3.1 b3.2 b3.2 b3.6 b3.4 b

Inventories

2.8 b3 b3 b2.9 b2.7 b2.6 b2.5 b2.6 b2.7 b2.7 b2.9 b3 b2.9 b

Current Assets

30.7 b28.3 b34.3 b36 b35.1 b37.7 b38.8 b42.2 b42.9 b45.8 b46.5 b48.4 b49.8 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

5.1 b5.2 b6.9 b7.7 b

Accounts Receivable

(38 m)136 m(420 m)(214 m)

Inventories

(7 m)327 m481 m(80 m)

Accounts Payable

(184 m)405 m(12 m)(44 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Net Income

1.4 b1.1 b1.5 b1.2 b1.6 b
USDY, 2017

EV/EBIT

66.7 x

Revenue/Employee

300.7 k

Financial Leverage

2.5 x
Show all financial metrics

Amgen Market Value History

Amgen Median Salaries

Source: 437 public H-1B filings from Amgen

Amgen's Web-traffic and Trends

Amgen Online and Social Media Presence

Amgen News and Updates

Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster

The FDA dealt Novartis’ Sandoz unit a blow last summer when it issued a complete response letter for the company’s biosimilar version of Amgen’s blockbuster drug Neulasta. Today the Swiss drug giant took a big step forward to making a second pass at approval.

Amgen gets its shot at promoting Repatha to prevent heart attacks and strokes

Amgen has its long-awaited approval to tout Repatha as a cardiovascular prevention tool. On the basis of a massive CV outcomes trial unveiled in March, the FDA blessed the cholesterol drug to fend off heart attacks, strokes and bypass surgeries in patients with heart disease.

Brilliant Growth Rate Expected For Global Anemia Drug Market by 2022

Market Research Future has a half cooked research report on the Anemia Drugs market. global market for Anemia Drugs is expected to be around US$21.4 billion and is expected to grow at a CAGR of 8.4% to reach US$34.7 billion by the end of forecast period Posted via Industry Today. Follow us on Twitte…

Amgen - Company Profile, SWOT Analysis, Size, Share, Growth, Trends and Opportunities 2017

WiseGuyReports.com adds “Amgen Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report ”reports to its database. Posted via Industry Today. Follow us on Twitter @IndustryToday

Amgen quarterly profit tops expectations despite sales decline

(Reuters) - Amgen Inc reported higher-than-expected third quarter profit on Wednesday as lower costs and improved operating margins helped offset sales declines in some of its most important products.

FiercePharmaAsia—China’s new drug policy guidelines, Mylan-Biocon’s Neulasta biosim, C-Bridge hire

China’s national authorities released wide-ranging guidelines for drug policy change, the FDA rejected Mylan and Biocon’s biosimilar of Amgen’s Neulasta due to a manufacturing issue, and China’s investment shop C-Bridge has tapped ex-GlaxoSmithKline executive Hussain as a senior partner.
Show more

Amgen Company Life and Culture

You may also be interested in